Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20320456 | 0.78 | AOC3 (0.33) | — | |
| SCHEMBL9972335 | 0.76 | HTT (0.32) | HTTALDH1A1KMT2A | |
| SCHEMBL2889631 | 0.74 | HTT (0.31) | HTT | |
| SCHEMBL10573778 | 0.74 | HTT (0.31) | HTT | |
| SCHEMBL10748672 | 0.74 | POLB (0.33) | HTTPOLB | |
| SCHEMBL18865739 | 0.74 | HTT (0.38) | HTT | |
| SCHEMBL13093295 | 0.73 | AOC3 (0.31) | HTT | |
| SCHEMBL17380242 | 0.71 | — | — | |
| SCHEMBL13104379 | 0.71 | — | — | |
| SCHEMBL16991801 | 0.71 | PDE4A (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023164236-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023164235-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023083285-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023083286-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-19 | — | — | WO | disclosed |
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3439653-B1 | REDUCING TUMOR BURDEN BY ADMINISTERING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | CHEMOCENTRYX INC (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2019-10-24 | — | — | US | disclosed |
| WO-2017109858-A1 | CONDENSED 11-MEMBERED RING COMPOUND, AND AGRICULTURAL AND HORTICULTURAL GERMICIDE INCLUDING SAME | 株式会社エス・ディー・エス バイオテック | 2017-06-29 | — | — | WO | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-7842693-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| WO-2010089993-A1 | RING-FUSED 2-PYRIDONE DERIVATIVES AND HERBICIDES | クミアイ化学工業株式会社 (JP) | 2010-08-12 | — | — | WO | disclosed |
| US-20100197674-A1 | OXOPYRAZINE DERIVATIVE AND HERBICIDE | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197674-A1 | OXOPYRAZINE DERIVATIVE AND HERBICIDE | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| EP-2174934-A1 | OXOPYRAZINE DERIVATIVE AND HERBICIDE | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-20100063067-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-11 | — | — | US | disclosed |
| US-7589199-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| WO-2008074991-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074991-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008042925-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | HTT 2300/4885ALDH1A1 569/4885KMT2A 909/4885 |
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | HTT 584/4885ALDH1A1 865/4885KMT2A 40/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | HTT 2300/4885ALDH1A1 569/4885KMT2A 909/4885 |
| US-20100063067-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CXCR1, CCR1, ACKR3 | HTT 4690/4885ALDH1A1 740/4885KMT2A 4081/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | HTT 4049/4885ALDH1A1 649/4885KMT2A 2804/4885 |
| US-20100197674-A1 | OXOPYRAZINE DERIVATIVE AND HERBICIDE | CBR3, CBR1, DDT | HTT 2517/4885ALDH1A1 1180/4885KMT2A 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.